Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference

Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a
Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
Proof-of-Concept Data at 12th International Conference on the Mechanisms and
Treatment of Neuropathic Pain

NOVATO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp.
(Nasdaq: RPTP), today announced that data from a clinical trial of NGX426, the
Company's orally administered non-opioid, AMPA/kainate antagonist, will be
presented at the 12th International Conference on the Mechanisms and Treatment
of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

Mark Wallace, M.D., Professor of Clinical Anesthesiology at the Center for
Pain Medicine of the University of California at San Diego ("UCSD") will
present results from a proof of concept clinical trial titled, "NGX426, An
Oral AMPA-Kainate Antagonist, is Effective in Human Capsaicin Induced
Hyperalgesia Model." NGX426 is a prodrug of Raptor's parenterally administered
product candidate tezampanel. When given subcutaneously and intravenously
tezampanel demonstrated statistically significant analgesic effect in five
Phase II trials. The five trials were completed in acute migraine,
nociceptive pain and neuropathic pain models.

The objective of the single center, double-blind, randomized study conducted
by Dr. Wallace was to demonstrate that the orally administered prodrug NGX426,
maintains the analgesic effect previously shown for the active moiety
tezampanel. Using a cross-over design, a total of 18 study subjects received
single doses of 90 mg of NGX426, 150 mg of NGX426 or placebo in each of three
treatment periods. Pain was induced by injecting 250 ug of capsaicin between
layers of skin in the forearm at 30 minutes and 120 minutes after dosing.

Results and details of the study will be presented on November 20, 2009 during
Dr. Wallace's presentation.

Raptor's Chief Medical Officer, Patrice Rioux, M.D., Ph.D., said, "Tezampanel
and its oral prodrug NGX426 are the first glutamate receptor antagonists to be
tested in human pain trials with combined binding activity at the AMPA and
kainite receptor subtypes. In particular, this novel, non-opioid mechanism of
action is interesting in the context of neuropathic pain where multiple
therapies are typically used to manage the condition."

Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, commented, "We
are hopeful that once released this data will further demonstrate the
potential value of NGX426 in the treatment of migraine and chronic pain. We
plan to continue to explore our options with NGX426 in the treatment of pain,
which potentially include spinning-out or partnering this program, to ensure
that our shareholders receive the maximum value from this potentially
groundbreaking drug."

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (NASDAQ: RPTP) ("Raptor") is dedicated to speeding
the delivery of new treatment options to patients by working to improve
existing therapeutics through the application of highly specialized drug
targeting platforms and formulation expertise. Raptor focuses on underserved
patient populations where it can have the greatest potential impact. Raptor
currently has product candidates in clinical development designed to
potentially treat nephropathic cystinosis, non-alcoholic steatohepatitis
("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase ("ALDH2")
deficiency, and a non-opioid solution designed to potentially treat chronic
pain.

Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein ("RAP") and related proteins that are designed to
target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. These statements relate
to future events or our future results of operation or future financial
performance, including, but not limited to the following statements: the
potential value of tezampanel and NGX426 in the treatment of migraine, chronic
pain, and other diseases; Raptor's ability to spin out or partner the
tezampanel and NGX426 pain program; Raptor's ability to ensure that its
shareholders receive the maximum value from tezampanel and NGX426; that
tezampanel and NGX426 can be potentially groundbreaking drugs; and Raptor's
ability to successfully develop any of its product candidates. These
statements are only predictions and involve known and unknown risks,
uncertainties and other factors, which may cause the Company's actual results
to be materially different from these forward-looking statements. Factors
which may significantly change or prevent the Company's forward looking
statements from fruition include that Raptor may be unsuccessful in developing
any products or acquiring products; that Raptor's technology may not be
validated as it progresses further and its methods may not be accepted by the
scientific community; that Raptor is unable to retain or attract key employees
whose knowledge is essential to the development of its products; that
unforeseen scientific difficulties develop with the Company's process; that
Raptor's patents are not sufficient to protect essential aspects of its
technology; that competitors may invent better technology; that Raptor's
products may not work as well as hoped or worse, that the Company's products
may harm recipients; and that Raptor may not be able to raise sufficient funds
for development or working capital. As well, Raptor's products may never
develop into useful products and even if they do, they may not be approved for
sale to the public. Raptor cautions readers not to place undue reliance on any
such forward-looking statements, which speak only as of the date they were
made. Certain of these risks, uncertainties, and other factors are described
in greater detail in the Company's filings from time to time with the
Securities and Exchange Commission (the "SEC"), which Raptor strongly urges
you to read and consider, including the joint proxy statement/prospectus on
Form S-4 filed with the SEC on August 19, 2009; Raptor's annual report on Form
10-K filed with the SEC on March 27, 2009; Raptor's quarterly report on Form
10-Q filed with the SEC on August 11, 2009; Raptor's wholly-owned
subsidiary's, Raptor Pharmaceuticals Corp. ("RPC") Registration Statement on
Form S-1, as amended, that was declared effective on August 7, 2008; RPC's
annual report on Form 10-K filed with the SEC on October 28, 2009, all of
which are available free of charge on the SEC's web site at
http://www.sec.gov. Subsequent written and oral forward-looking statements
attributable to Raptor or to persons acting on its behalf are expressly
qualified in their entirety by the cautionary statements set forth in Raptor's
reports filed with the SEC. Raptor expressly disclaims any intent or
obligation to update any forward-looking statements.

For more information, please contact:
Karl Cahill, Investor Relations
(858) 531-6100
kcahill@raptorpharma.com

The Ruth Group

Sara Ephraim Pellegrino (investors)
(646) 536-7002
spellegrino@theruthgroup.com
Janine McCargo (media)
(646) 536-7033
jmccargo@theruthgroup.com

SOURCE Raptor Pharmaceutical Corp.

Karl Cahill, Investor Relations, +1-858-531-6100, kcahill@raptorpharma.com;
Sara Ephraim Pellegrino, (investors), +1-646-536-7002,
spellegrino@theruthgroup.com, or Janine McCargo, (media), +1-646-536-7033,
jmccargo@theruthgroup.com, both of The Ruth Group